CDC emphasizes importance of early antiviral treatment for hospitalized flu patients and those at risk of severe illness
Drug-resistant strains also detected in other countries such as Hong Kong during 2009 swine flu pandemic
These strains reduce effectiveness of oseltamivir but retain susceptibility to other antiviral drugs
Two new cases of drug-resistant H1N1 influenza with mutations I223V and S247N identified in the US
Vaccination recommended as best defense against influenza and its complications
Two new cases of drug-resistant H1N1 influenza, specifically the mutations I223V and S247N, have been identified in the United States by the Centers for Disease Control and Prevention (CDC) in labs at the Connecticut Department of Health and at the University of Michigan. These strains were first detected in May 2023 but have only recently gained attention due to their resistance to oseltamivir, a common antiviral medication sold under the brand name Tamiflu. However, these strains still retain susceptibility to other approved influenza antiviral drugs such as baloxavir.
The flu season usually ends by March, but these mutations have been spreading throughout southern US states at this time of year. The CDC is closely monitoring the situation and emphasizes the importance of early antiviral treatment for hospitalized flu patients and those at risk of severe illness.
These drug-resistant strains are not unique to the United States; they have also been detected in other countries such as Hong Kong, where scientists first identified them. The World Health Organization reported a confirmed 491,382 cases and 18,449 deaths globally during the 2009 swine flu pandemic caused by the H1N1 virus.
It is important to note that while these mutations may reduce the effectiveness of oseltamivir, they do not render it completely ineffective. The CDC continues to recommend vaccination as the best defense against influenza and its complications.
CDC warns of a new ‘dual mutant’ strain of H1N1 influenza that could pose a threat in the US.
At least two cases of this flu mutation have been confirmed in humans in the US.
The strains, I223V and S247N, have shown resistance to Tamiflu (oseltamivir), a common flu medication.
These strains retain susceptibility to other approved influenza antiviral drugs, including baloxavir.
Flu season is usually over by March, but this mutation has been spreading throughout southern US states at this time of year.
Accuracy
No Contradictions at Time
Of
Publication
Deception
(100%)
None Found At Time Of
Publication
Fallacies
(90%)
The article contains an appeal to authority and inflammatory rhetoric. It also uses a dichotomous depiction.
. . . the agency announced on Wednesday.
At least two cases of the flu mutations have been confirmed in humans in the U.S.,
The strains have been detected in 15 countries across five continents, but are mostly prevalent in Europe,
Dr. Marc Siegel, clinical professor of medicine at NYU Langone Medical Center and a Fox News medical contributor, said it is ‘highly unusual‘ to see an influenza A strain . . .
A study in Emerging Infectious Diseases identified H1N1 flu cases with reduced susceptibility to oseltamivir (Tamiflu) from May 2023 to February 2024.
The viruses showed a 13-fold reduced inhibition by oseltamivir while retaining normal susceptibility to other antiviral drugs.
Most detections were made in Europe, with the Netherlands having the most detections (30).
Gavi announced that lower-income countries can now apply to four new vaccine programs: Ebola for high-risk groups, rabies vaccine for postexposure prophylaxis, multivalent meningococcus, and hepatitis B.
Sysmex Astrego won the Longitude Prize for the development of a rapid antimicrobial susceptibility test for urinary tract infections (UTIs).
CARB-X announced that it will award Fuse Diagnostics up to $1 million to develop a rapid diagnostic test for chlamydia and gonorrhea.
An at-home antibody test can gauge users’ immunity to COVID-19, alerting to the need for a vaccine booster dose.
Accuracy
At least two cases of this flu mutation have been confirmed in humans in the US.
These strains retain susceptibility to other approved influenza antiviral drugs, including baloxavir.
Two cases of 'dual mutant' strains of influenza A, or H1N1, have been detected in the United States.
These genetic changes might make flu treatments less effective.
Newer antiviral medication baloxavir also demonstrated reduced susceptibility to these strains.
Accuracy
At least two cases of this flu mutation have been confirmed in humans in the US.
The most commonly prescribed treatment for influenza, oseltamivir (Tamiflu), may be less effective against these mutated viruses due to the I223V and S247N mutations.
The Centers for Disease Control and Prevention (CDC) identified two new cases of H1N1 influenza in the United States that are more resistant to medication.
The mutations, called I223V and S247N, were first detected in labs at the Connecticut Department of Health and at the University of Michigan this past fall and winter.
Accuracy
At least two cases of this flu mutation have been confirmed in humans in the US.
These strains, I223V and S247N, have shown resistance to Tamiflu (oseltamivir), a common flu medication.
